Caspase inhibitors: A pharmaceutical industry perspective

Current Topics in Medicinal Chemistry

Volumn 5, Issue 16, 2005, Pages 1697-1716

  Linton, Steven D ^a  

^a PFIZER INC   (United States)

Author keywords

Fas induced liver model; Apoptosis; Caspase inhibitor; ICE; IDN 6556; Jurkat; Peptidomimetics; VX 740; VX 765

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALPHA INTERFERON; AZEPINE DERIVATIVE; CASPASE INHIBITOR; CGP 82630; CYSTEINE PROTEINASE INHIBITOR; IDN 1965; IDN 5370; IDN 7866; LB 84318; M 791; M 808; M 826; M 867; M 920; METHOTREXATE; MX 1013; MX 1122; MX 1153; PRALNACASAN; RIBAVIRIN; RU 36384; SULFONAMIDE; UNCLASSIFIED DRUG; VRT 18858; VX 765; VX 799; XYZ 033MP;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENTERITIS; ENZYME INHIBITION; HEART INFARCTION; HUMAN; LIVER FIBROSIS; LIVER INJURY; NONHUMAN; OSTEOARTHRITIS; REVIEW; SEPSIS; STROKE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CASPASES; CYSTEINE PROTEINASE INHIBITORS; DRUG INDUSTRY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645056953     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605775009720     Document Type: Review

References (137)

1. Ellis, R. E.; Yuan, J.; Horvitz, H. R. Mechanisms and Functions of Cell Death. Annu. Rev. Cell Biol. 1991, 7, 663.
2. Reed, J. C.; Tomaselli, K. J. Drug discovery opportunities from apoptosis research. Cur. Opin. Biotech. 2000, 11, 586.
3. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000 407, 810-816.
4. Reed, J. Apoptosis based therapies. Nat. Rev. Drug. Disc. 2002 1, 111-121.
5. MacBride, C. B.; McPhail, L. T.; Sleeves, J. D. Emerging therapeutic targets in caspase-dependent disease. Emer. Thera. Targ. 1999, 3, 391-411.
6. For nomenclature of the caspase family, see: Alnemri, E. S.; Livingston, D. J.; Nicholson, D. W.; Salvesen, G.; Thornberry, N. A.; Wong, W. W.; Yuan, J.-Y. Human ICE/ced-3 rotease nomenclature. Cell 1996 87, 171.
7. Thornberry, N. A. Caspases: Key mediators of apoptosis. Chem. Biol. 1998 5, R97.
8. Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Ann. Rev. Biochem. 1999, 68, 383-424.
9. Fuentes-Prior, P.; Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation, and inhibition. Biochem. J. 2004, 384, 201-232.
10. Black, R. A.; Kronheim S. R.; Sleath, P. R. Activation of interleukin-1b by a co-induced protease. FEBS Lett. 1989, 247, 386.
11. Ayala, J. M.; Yamin, T. T.; Egger, L. A.; Chin, J.; Kostura, M. K.; Miller, D. K. IL-1beta-converting enzyme is present in monocytic cells as an inactive 45-kDa precursor. J. Immunol. 1994 153, 2592-2599.
12. Thornberry, N. A.; Molineaux, S. M. Interleukin-1beta converting enzyme: A novel cysteine protease required for IL-1beta production and implicated in programmed cell death. Protein Science 1995, 4, 3-12.
13. Dinarello, C. A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 2004, 4, 378-385.
14. Martel-Pelletier, J. Proinflammatory mediators and osteoarthritis. Osteo. Cart. 1999, 7, 315-316.
15. Siegmund, B.; Lehr, H. A.; Fantuzzi, G.; Dinarello, C. A. 1L-beta-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 2001, 98, 13249-13254.
16. Nakae, S.; Komiyama, Y.; Yokoyama, H.; Nambu, A.; Umeda, M.; Iwase, M.; Homma, I.; Sudo, K.; Horai, R.; Asano, M.; Iwakura, Y. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int. Immunol. 2003, 15, 483-490.
17. Schmitz, N.; Kurrer, M.; Kopf, M. The IL-1 receptor is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur. J. Immunol. 2003, 33, 991-1000.
18. Iwata, A.; Nishio, K.; Winn, R. K.; Chi, E. Y.; Henderson, W. R.; Harlan, J. M. A broad-spectrum caspase inhibitor attenuates allergic airway inflammation in murine asthma model. J. Immunol. 2003, 170, 3386-3391.
19. Talanian, R. V.; Brady, K. D.; Cryns, V. L. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J. Med. Chem. 2000, 43, 3351.
20. Legos, J. J.; Lee, D.; Erhardt, J. A. Caspase inhibitors as neuroprotective agents. Emerging Drugs 2001, 6, 81-94.
21. Graczyk, P. P. Caspase inhibitors as anti-inflammatory and antiapoptotic agents. Progress in Medicinal Chemistry 2002, 39, 1-72.
22. O'Brien, Tom; Lee, Dennis. Prospects for caspase inhibitors. Mini-Rev. Med. Chem. 2004, 4, 153-165.
23. Ashwell, S. Caspases: Recent advances in small molecule inhibitors. Exp. Opin. Ther. Patents 2001, 11, 1593.
24. Dolle, R. E.; Chaturvedula, P. V.; Ross, T. M.; Schmidt, S. J. Fused bicyclic lactams as interleukin-1 beta converting enzyme inhibitors. U.S. Patent 5, 552, 400, Sept. 3, 1996.
25. Dolle, R. E.; Prasad, C. V. C.; Prouty, C. P.; Salvino, J. M.; Awad, M. M. A.; Schmidt, S. J.; Hoyer, D.; Ross, T. M.; Graybill, T. L.; Speier, G. J.; Uhl, J.; Miller, B. E.; Helaszek, C. T.; Ator, M. A. Pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interlettkin-1b-converting enzyme inhibitor. J. Med. Chem. 1997, 40, 1941.
26. Chem, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R. An efficient stereoselective synthesis of [3S(1S, 9S)]-3- [9-(Benzoylamino ) octahydro-6,10-dioxo-6H-pyridazino-(1,2)-diazepin-1-yl] -carbonyl]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1587-1592.
27. Batchelor, M. J.; Bebbington, D.; Bemis, G. W.; Fridman, W. H.; Gillespie, R. J.; Golec, J. M. C.; Gu, Y.; Lauffer, D. J.; Livingston, D. J.; Matharu, S. S.; Mullican, M. D.; Murck, M. A.; Murdoch, R.; Nyce, P. L.; Robidoux, A. L. C.; Su, M.; Wannamaker, M. W. Inhibitors of interleukin-1beta converting enzyme. WO97/22619, June 26, 1997.
28. Freidman, W. H.; Murdoch, R.; Batchelor, M. J.; Bebbington, D.; Gillespie, R. J.; Golec, J. M. C.; Matharu, S. S.; Robidoux, A. L. C.; Bemis, G. W.; Gu, Y.; Murcko, M. A.; Nyce, P.; Lauffer, D. J.; Su, M.; Wilson, K. P.; Zelle, R. E.; Livingston, D. J.; Mullican, M. D.; Wannamaker, M. Inhibitors of interleukin-1beta converting enzyme. U.S. Patent 6,204,261, March 20, 2001.
29. A related core: Lauffer, D. J.; Mullican, M. D. A practical synthesis of (S) 3-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-1, 5-benzodiazepine-1-acetic acid methyl ester as a conformationally restricted dipeptide-mimetic for caspase-1 (ICE) inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1225-1227.
30. Randle, J. C.; Harding, M. W.; Ku, G.; Shonharting, M.; Kurrle, R. ICE/ Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs 2001, 10, 1207-1209.
31. Leung-Toung, R., Li, W.; Tam, T. F.; Karimian, K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. 2002, 9, 979-1002.
32. Siegmund B, Zeitz M. Pralnacasan. IDrugs 2003, 6, 154-158.
33. Ku, G.; Ford, P.; Raybuck, S. A.; Harding, M. W.; Randle, J. C. R. Selective interleukin-1beta converting enzyme (ICE/Caspase-1) inhibition with Pralnacasan (HMR 3480/VX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA). 65th Annual Meeting American College of Rheumatology, San Francisco, November 2001, Abstract #1134.
34. Rudolphi, K.; Gerwin, N.; Verzijl, N.; van der Kraan, P.; van den Berg, W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003, 11, 738-46.
35. Wannamaker, M. W.; Bemis, G. W.; Charifson, P. S.; Lauffer, D. J.; Mullican, M. D.; Murcko, M. A. Caspase inhibiting amide derivatives, WO99/47545, Sept 23, 1999.
36. Wannamaker, M.; Davies, R. Prodrug of an ICE inhibitor. WO 01/90063, Nov. 29, 2001.
37. Loher, F.; Bauer, C.; Landauer, N.; Schmall, K.; Siegmund, B.; Lehr, H. A.; Dauer, M.; Schoenharting, M.; Endres, S.; Eigler, A. The interleukin-1beta-converting enzyme inhibitor Pralnacasan reduces dextran sulfate sodium-induced murine colitis and T-helper 1 T-cell activation. J. Pharm. Exp. Ther. 2004, 308, 583-590.
38. Siegmund, B. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem. Pharmacol. 2002, 64, 1-8.
39. Bauer, C.; Loher, F.; Schmall, K.; Hallwachs, R.; Loehr, C.; Siegmund, B.; Dauer, M.; Lehr, H. A.; Schoenharting, M.; Endres, S.; Eigler, A. In vivo efficacy of the interleukin-1beta-converting enzyme inhibitor Pralnacasan in DSS- induced murine colitis. Gastroenterology 2002, 122 (Suppl. 1), T971.
40. Golec, J.; Charifson, P.; Brechley, G. Caspase inhibitors and uses thereof WO 01/010383, Feb. 15, 2001.
41. Golec, J.; Charifson, P.; Charrier, J. D.; Birch, H. Caspase inhibitors and uses thereof. WO 01/042216, June 14, 2001.
42. Bebbington, D.; Charrier, J. D.; Kay, D.; Knegtel, R.; Golec, J.; Mortimore, M.; Studley, J. Carbamate caspase inhibitors and uses thereof. WO 01/072707, Oct. 4, 2001.
43. Golec, J. Caspase inhibitors and uses thereof. WO 01/090070, Nov. 29, 2001.
44. Brenchley, G.; Charrier, J. D. Caspase inhibitors and uses thereof. WO 01/094351, Dec. 13, 2001.
45. Mortimore, M.; Knegtel, R.; Charrier, J. D. Caspase inhibitors and uses thereof. WO 02/022611, March 21, 2002.
46. Kay, D.; Golec, J. Imidazole and benzimidazole caspase inhibitors and uses thereof. WO 02/042278, May 30, 2002.
47. Diu-Hercend, A.; Golec, J.; Hercend, T.; Knegtel, R.; Lang, P.; Miller, A.; Miller, K.; Mortimore, M.; Weber, P. Heterocyclicdicarbamides as caspase inhibitors. WO 02/085899, Oct. 31, 2002.
48. Mortimore, M.; Miller, A.; Studley, J.; Charrier, J. D. Caspase inhibitors and uses thereof WO 02/094263, Nov. 28, 2002.
49. Mortimore, M.; Golec, J. Phospholipids as caspase inhibitor prodrugs. WO 03/068242, Feb. 11, 2003.
50. Miller, K.; Diu-Hercend, A.; Lang, P.; Weber, P.; Golec, J.; Mortimore, M. Regulation of TNF alpha. WO 03/088917, Oct. 30, 2003.
51. Knegtel, R.; Mortimore, M,; Studley, J.; Milian, D. Caspase inhibitors and uses thereof WO 04/002961, Jan. 8, 2004.
52. Charrier, J. D.; Mortimore, M.; Studley, J. 4-oxo-3-(1-oxo-1H-isoquinolino- 2-ylacetylamino)-pentanoic acid ester and amide derivatives and use as caspase inhibitors. WO 04/058718, July 15, 2004.
53. Allen, H. J.; Brady, K. D.; Harter, W. G.; Lunney, E. A.; Plummer, M. S.; Sawyer, T. S.; Shahripour, A.; Walker, N. Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors. U.S. Patent 6,083,981, July 4, 2000.
54. Albrecht, H. P.; Allen, H. J.; Brady, K. D.; Harter, W. G.; Kostlan, C. R.; Roth, B. A.; Walker, N. Sulfonamide interleukin-1beta converting enzyme inhibitors. U.S. Patent 6,316,415, November 13, 2001.
55. Shahripour, A. B.; Plummer, M. S.; Lunney, E. A.; Albrecht, H. P.; Hays, S. J.; Kostlan, C. R.; Sawyer, T. K.; Walker, N. P. C.; Brady, K. D.; Allen, H. J.; Talanian, R. V.; Wong, W. W.; Humblet, C. Structure-based design of nonpeptide inhibitors of interieukin-1b converting enzyme (ICE, Caspase-1). Bioorg. Med. Chem. 2002, 10, 31-40.
56. Shahripour, A. B.; Plummer, M. S.; Lunney, E. A.; Sawyer, T. K.; Stankovic, C. J.; Connolly, M. K.; Rubin, J. R.; Walker, N. P. C.; Brady, K. D.; Allen, H. J.; Talanian, R. V.; Wong, W. W.; Humblet, C. Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide. Bioorg. Med. Chem. Lett. 2001, 11, 2779-2782.
57. Harter, W. G.; Albrecht, H.; Brady, K.; Caprathe, B.; Dunbar, J.; Gilmore, J.; Hays, S.; Kostlan, C. R.; Lunney, B.; Walker, N. The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 809-812.
58. De, B.; Demuth, T. P.; Laufersweiler, M. C.; O'Neill, S. V.; Oppong, K. A.; Soper, D. L.; Wang, Y.; Wos, J. A.; O'Neil, S. V. New azepine and thiazeran derivatives, useful for treating e.g. myocardial ischemia, reperfusion injury, endotoxic shock and multiple sclerosis (ICE inhibitors). WO 03/103677, 2003.
59. De, B.; Demuth, T. P.; Laufersweiler, M. C.; O'Neill, S. V.; Oppong, K. A.; Soper, D. L.; Wang, Y.; Wos, J. A.; Chen, J.; O'Neil, S. V. New 8,6-fused ring heterocycles useful for the treatment of e.g. acute and chronic inflammatory-mediated, autoimmune, infectious diseases, diabetes and osteoporosis. WO 03/104231, 2003.
60. Chen, J.; De, B.; Demuth, T. P.; Laufersweiler, M. C.; O'Neil, S. V.; Oppong, K. New 5-oxo-1,2,3,5,6,7,10,10a-octahydro-pyrrolo (1,2-a)azoeine derivatives useful for treating e.g. osteoarthritis, acute and chronic inflammatory mediated diseases, autoimmune diseases and diabetes. WO 03/ 106460, 2003.
61. Choong, I. C.; Lew, W.; Lee, D.; Pham, P.; Burdett, M. T.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Fahr, B.; DeLano, W. L.; McDowell, R S.; Allen, D. A.; Erlanson, D. A.; Gordon, E. M.; O'Brien, T. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J. Med. Chem. 2002, 45, 5005-5022.
62. Allen, D.; Pham, P.; Choong, I.; Fahr, B.; Burdett, M.; Lew, W.; DeLano, W.; Gordon, E.; Lam, J.; O'Brien, T.; Lee, D. Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorg. Med. Chem. Lett. 2003, 13, 3651-3655.
63. Erlanson, D.; Lam, J.; Wiesmann, C.; Luong, T,; Simmons, R.; DeLano, W.; Choong, I.; Burdett, M,; Flanagan, M.; Lee, D.; Gordon, E.; O'Brien, T. In situ assembly of enzyme inhibitors using extended tethering. Nature Biotech. 2003, 21, 308-314.
64. Wu, J. C.; Fritz, L. C. Irreversible caspase inhibitors: Tools for Studying apoptosis. Methods: A Companion to Methods Enzymol. 1999, 17, 320.
65. Keana, J. F. W.; Cai, S. X.; Guastella, J.; Yang, W.; Drewe, J. A. Dipeptides apoptosis inhibitors and the use thereof. WO 99/018781, April 22, 1999.
66. Cai, S. X.; Drewe, J.; Wang, Y.; Weber, E. Preparation of dipeptide caspase inhibitors. WO 99/047154, Sept. 23, 1999.
67. Cai, S. X; Wang, Y.; Weber, E.; Mills, G. B.; Green, D. R. Preparation of substituted 2-aminobenzamides as caspase inhibitors. WO 00/055114, Sept. 21, 2000.
68. Cai, S. X.; Weber, E.; Wang, Y.; Mills, G. B.; Green, D. R Preparation of peptides as caspase inhibitors. WO 00/061542, Oct. 19, 2000.
69. Preparation of dipeptide apoptosis inhibitors. Keana, J. F. W.; Cai, S. X.; Guastella, J.; Yang, W.; Drewe, J.A. US Patent 6,184,210, 2001.
70. Wang, Y.; Cai, S. X.; Weber, E.; Mills, G. B.; Green, D. R.; Guan, L. Preparation of substituted a-hydroxyacyl amino acid derivatives as caspase inhibitors. WO 01/016093, March 8, 2001.
71. Cai, S. X.; Wang, Y.; Huang, J. C.; Guastella, J.; Wu, Y.; Xue, D.; Drewe, J. CV 1013, a novel, potent, and irreversible pan-caspase inhibitor with activity in animal models of hepatitis, stroke, and myocardial infarction. Abstracts of Papers, 220th ACS National Meeting, Washington, DC, United States, August 20-24, 2000, MEDI-153.
72. Yang, W.; Guastella, J.; Huang, J. C.; Wang, Y.; Zhang, L.; Xue, D.; Tran, M.; Woodward, R.; Kasibhatla, S.; Tseng, B.; Drewe, J.; Cai, S. X. MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br. J. Pharmacol. 2003, 140, 402-412,
73. Cai, S. X; Guan, L.; Jia, S.; Wang, Y.; Yang, W.; Tseng, B.; Drewe, J. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg. Med. Chem. Lett. 2004, 14, 5295-5300.
74. Wang, Y.; Guan, L.; Jia, S.; Tseng, B.; Drewe, J.; Cai, S. X. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 a-amino acid by an a-hydroxy acid. Bioorg. Med. Chem. Lett. 2005, 15, 1379-1383.
75. Chereau, D.; Kodandapani, L.; Tomaselli, K. J.; Spada, A. P.; Wu, J. C. Structural and functional analysis of caspase active sites. Biochemistry 2003, 42, 4151-4160.
76. Hotchkiss, R. S.; Chang, K. C.; Swanson, P. E.; Tinsley, K. W.; Hui, J. J.; Mender, P.; Xanthoudakis, S.; Roy, S.; Black, C.; Grimm, E.; Aspiotis, R.; Han, Y.; Nicholson, D. W.; Karl, I. E. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nature Immunol 2000, 1, 496-501.
77. Anel, R. L.; Kumar, A. Experimental and emerging therapies for sepsis and septic shock. Exp. Opin. Invest. Drugs 2001, 10, 1471-1485.
78. Han, Y.; Giroux, A.; Colucci, J.; Bayly, C. I.; McKay, D. J.; Roy, S.; Xanthoudakis, S.; Vaillancourt, J.; Rasper, D. M.; Tam, J.; Tawa, P.; Nicholson, D. W.; Zamboni, R. J. Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1173-1180.
79. Han, Y.; Giroux, A.; Zamboni, R.; McKay, D.; Bayly, C.; Grimm, E.; Colucci, J. Pyrazinones, compositions containing such compounds. WO01/ 05772, Jan. 25, 2001.
80. Han, B. H.; Xu, D.; Choi, J.; Han, Y.; Xanthoudakis, S.; Roy, S.; Tam, J.; Vaillancourt, J.; Colucci, John; Siman, R.; Giroux, A.; Robertson, G. S.; Zamboni, R.; Nicholson, D. W.; Holtzman, D. M. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J Biol. Chem. 2002, 277, 30128-30136.
81. Colucci, J.; Giroux, A.; Zhu, Y.; Bouche, M.; Pikounis, B.; Xanthoudakis, S.; Roy, S.; Rigby, M.; Zamboni, R.; Robertson, G. S.; Ng, G. Y.; Nicholson, D. W.; Fluckiger, J. P.; Toulmond, S.; Tang, K.; Bureau, Y.; Ashdown, H.; Degen, S.; O'Donnell, R.; Tam, J.; Han, Y. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br. J. Pharmacol. 2004 141, 689-97.
82. Robertson, G. S.; Crocker, S. J.; Nicholson, D. W.; Schulz, J. B. Neuroprotection by the inhibition of apoptosis. Brain Pathol. 2000, 10, 283-292.
83. Schulz, J. B. Caspases and neurodegeneration: a potential therapeutic target. Cur. Op. Cen. Periph. Nerv. Sys. Invest. Drugs 2000, 2, 417-422.
84. Rideout, H. J.; Stefanis, L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Hist. Histopath 2001, 16, 895-908.
85. Me'thott, N.; Huang, J. Q.; Coulombe, N.; Vaillancourt, J. P.; Rasper, D.; Tam, J.; Hanm Y.; Colucci, J.; Zamboni, R.; Xanthoudakis, S.; Nicholson, D. W.; Roy, S. Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. J. Exp. Med. 2004 199, 199-207.
86. Me'thott, N.; Vaillancourt, J. P.; Huang, J. Q.; Colucci, J.; Han, Y.; Menard, S.; Zamboni, R.; Toulmond, S.; Nicholson D. W.; Roy, S. A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation. J. Biol. Chem. 2004, 279, 27905-27914.
87. Colucci, J.; Giroux, A.; Han, Y.; Methot, N.; Nicholson, D. W.; Roy, S.; Vaillancourt, J. P.; Tawa, P. Preparation of peptidyl irreversible caspase-3 inhibitors as active site probes. WO 04/069773, August 19, 2004.
88. Becker, J. W.; Rotonda, J.; Soisson, S. M., Aspiotis, R.; Bayly, C.; Frncoeur, S.; Gallant, M.; Garcia-Calvo, M; Giroux, A.; Grimm, E.; Han, Y.; McKay, D.; Nicholson, D. W.; Peterson, E.; Renaud, J.; Roy, S.; Thornberry, N.; Zamboni, R. Reducing the peptidyl features of caspase-3 inhibitors: A structural analysis. J. Med. Chem. 2004, 47, 2466-2474.
89. Grimm, E. L.; Roy, B.; Aspiotis, R.; Bayly, C. I.; Nicholson, D. W.; Rasper, D. M.; Renaud, J.; Roy, S.; Tam, J.; Tawa, P.; Vaillancourt, J. P.; Xanthoudakis, S.; Zamboni, R. J. Solid phase synthesis of selective caspase-3 peptide inhibitors. Bioorg. Med. Chem. 2004, 12, 845-851.
90. Nicotinyl Patent: Black, C.; Grimm, E. L.; Isabel, E.; Renaud, J. Nicotinyl aspartyl ketones as inhibitors of caspase-3. WO 01/27085, April 19, 2001.
91. Isabel, E.; Black, W. C.; Bayly, C. I.; Grimm, E. L.; Janes, M. K.; McKay, D. J,; Nicholson, D. W.; Rasper, D. M.; Renaud, J.; Roy, S.; Tam, J.; Thornberry, N. A.; Vaillancourt, J. P.; Xanthoudakis, S.; Zamboni, R. Nicotinyl aspartyl ketones as inhibitors of caspase-3. Bioorg. Med. Chem. Let. 2003, 13, 2137-2140.
92. Han, Y.; Giroux, A.; Grimm, E. L.; Aspiotis, R.; Francoeur, S.; Bayly, C. I.; McKay, D. J.; Roy, S.; Xanthoudakis, S.; Vaillancourt, J. P.; Rasper, D. M.; Tam, J.; Tawa, P.; Thornberry, N. A.; Paterson, E. P.; Garcia-Calvo, M.; Becker, J. W.; Rotonda, J.; Nicholson, D. W.; Zamboni, R. J. Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 805-808.
93. Willoughby, C. A.; Chapman, K. T. Granzyme B inhibitors. WO 03/065987 August 14, 2003,
94. Willoughby, C. A.; Bull, H. G.; Garcia-Calvo, M.; Jiang, J.; Chapman, K. T.; Thornberry, N. A. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL-mediated apoptosis. Bioorg. Med. Chem. Lett. 2002, 12, 2197-2200.
95. Park, T. K.; Chang, H. K.; Chung, H. H; Min, C. H.; Oh, Y. L.; Park, M. J.; Lee, T. H.; Moon, K. Y.; Kim, E. K. Caspase inhibitor. WO 01/21599, March 21, 2001.
96. Kim, E. K.; Park, M. J.; Lee, T. H.; Chang, H. K.; Park, T. K.; Kang, C. Y.; Kim, Y. M.; Moon, K. Y.; Oh, Y. L.; Min, C. H.; Chung, H. H. Caspase inhibitors. WO 01/21600, March 29, 2001.
97. Kim, K.; Kim, Y. M.; Park, M.; Park, K.; Chang, H. K.; Park, T. K.; Chung, H. H.; Kang, C. Y. A broad-spectrum inhibitor blocks concanavalin A-induced hepatitis in mice. Clin. Immunol. 2000, 97, 221-233.
98. Chang, H. K.; Park, M.; Park, J.; Kim, S.; Oh, Y. Discovery of a novel caspase inhibitor and protection of liver damage in mouse models. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004, MEDI-267.
99. Park, M.; Park, J. G.; Kim, S. S.; Oh, Y. S.; Chang, H. K.; Kim, C. H.; Kang, S. H. LB84318, A Novel and Small-molecule caspase inhibitor, Potently Protects Liver Damage in Mouse Models of Liver Injury. Abstracts of Papers, 55th American Association for the Study of Liver Diseases, Boston, MA, United States, October 29-November 2, 2004, abstract # 1215.
100. Bai, X.; Karanewsky, D. S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases. US Patent 5,877,197, Feb. 9, 1999.
101. Bai, X.; Karanewsky, D. S. C-terminal modified (N-substituted)-2-indolylcarbonyl dipeptides as inhibitors of the ICE/ ced-3 family of cysteine proteases. US Patent 6,184,244, Feb. 6, 2001.
102. Karanewsky, D. S.; Linton, S. D. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes. US Patent 5,968,927, 1999.
103. Roggo, S.; Hintermann, S.; Rasetti, V.; Von Krosigk, U. Hexahydro-4-oxoazepino[3,2,1-HI]indoles, WO 02/034751, May 2,2002.
104. [10 4] Fritz, L. C.; Tomaselli, K. J.; Karanewsky, D. S.; Linton, S. D.; Bai, X. Inhibition of apoptosis using ICE/ced-3 family inhibitors. US Patent 6,200,969, Dec. 13, 2001.
105. Roggo, S.; Hintermann, S.; Rasetti, V.; Von Krosigk, U. Malonates as inhibitors of the ICE/ced-6 family of cysteine proteases. WO 02/076968 Oct. 3, 2002.
106. Kalish, V. J.; Karanewsky, D. S.; Robinson, E. D.; Ullman, B. R. (Substituted) Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases. US Patent 6,242,422, June 5, 2001.
107. Karanewsky, D. S.; Ternansky, R. J. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases. U.S. Patent, 6,197,750, 2001.
108. Karanewsky, D. S.; Ternansky, R. J.; Linton, S. D.; Dinh, T. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases. WO 02/057298, July 25, 2002.
109. Linton, S. D.; Karanewsky, D. S.; Ternansky, R. J.; Wu, J. C.; Pham, B.; Kodandapani, L.; Smidt, R.; Diaz, J. L.; Fritz, L. C.; Tomaselli, K. J. Acyl dipeptides as reversible caspase inhibitors. Part 1: Initial lead optimization. Bioorg. Med. Chem. Lett. 2002, 12,2969.
110. Linton, S. D.; Karanewsky, D. S.; Ternansky, R. J.; Chen, N.; Guo, X; Jahangiri, K. G.; Kalish, V. J.; Meduna, S. P.; Robinson, E. D.; Ullman, B. R.; Wu, J. C.; Pham, B.; Kodandapani, L.; Smidt R.; Diaz, J. L.; Fritz, L. C.; Krosigk, U.; Roggo, S.; Schmitz, A.; Tomaselli, K. J. Acyl dipeptides as reversible caspase inhibitors. Part 2: Further optimization. Bioorg Med. Chem. Lett. 2002, 12, 2973.
111. Ullman, B. R.; Aja, T.; Deckwerth, T. L.; Diaz, J. L.; Herrman, J.; Kalish, V. J.; Karanewsky, D. S.; Meduna, S. P.; Nalley, K.; Robinson, E. D.; Roggo, S. P.; Sayers, R. O.; Schmitz, A.; Temansky, R. J.; Tomaselli, K. J.; Wu, J. C. Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications. Bioorg. Med. Chem. Lett. 2003, 13, 3623-3626.
112. Brady, K. D. Bimodal inhibition of caspase-1 by aryloxymethyl and acyloxymethyl ketones. Biochemistry 1998, 37, 8508-8515.
113. Brady, K. D.; Giegel, D. A.; Grinnell, C.; Lunney, E.; Talanian, R. V.; Wong, W.; Walker, N. A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones. Bioorg. Med. Chem. 1999, 7, 621-631.
114. Linton, S. D.; Aja, T.; Allegrini, P. R.; Deckwerth, T. L.; Diaz, J. L.; Hengere, B.; Herrman, J.; Jahangiri, K. G.; Kallen, J.; Karanewsky, D. S.; Meduna, S. P.; Nalley, K.; Robinson, E. D.; Roggo, S.; Rovelli, G.; Sauter, A.; Sayers, R. O.; Schmitz, A.; Smidt, R.; Ternansky, R. J.; Tomaselli, K. J.; Ullman, B. R.; Wiessner, C.; Wu, J. C. Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. Bioorg. Med. Chem. Lett. 2004, 14, 2685-2691.
115. Hintermann, S.; Roggo, S. P.; von Krosigk, U. I.; Tintelnot-Blomley, M. R.; Rasetti, V. G.; Leutert, T.; Auer, K. K.; Wu, J.; Tomaselli, K. P2/3 Oxo azepinoindoles: Optimized synthesis and structure activity relationship of a potent, brain penetrable caspase inhibitor series. Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001.
116. Roggo, S. P.; Hintermann, S.; Rasetti, V. G.; von Krosigk, U. I.; Tintelnot-Blomley, M. R.; Kallen, J. A.; Schmitz, A.; Rovelli, G. F.; Hengerer, B.; Ortmann, R.; Sauter, A.; Wiessner, C.; Allegrini, P. R.; Karanewsky, D. S.; Linton, S. D.; Ternansky, R. J.; Wu, J.; Tomaselli, K. P2/3 Oxo azepinoindoles: A new class of potent broad spectrum caspase inhibitors with in vivo activity in the pMCAO model. Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001.
117. Deckwerth, T. L.; Adams, L. M.; Wiessner, C.; Allegrini, P. R.; Rudin, M.; Sauter, A.; Hengerer, B.; Sayers, R. O.; Rovelli, G.; Aja, T.; May, R.; Nalley, K.; Linton, S. D.; Karanewsky, D. S.; Wu, J. C.; Roggo, S.; Schmitz, A.; Contreras, P, C.; Tomaselli, K. J. Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. Drug Develop. Res. 2001, 52, 579-586.
118. Galle, P. R.; Hofmann, W. J.; Walczak, H.; Schaller, H.; Otto, G.; Stremmel, W.; Krammer, P. H.; Runkell, L. Involvement of the CD95 (APO-1/ Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182, 1223-1230.
119. Patel, T.; Gores, G. J. Apoptosis and hepatobilliary disease. Hepatology, 1995, 21, 1725-1741.
120. Natori, S.; Rust, C.; Stadheim, L. M.; Srinivasan, A.; Burgari, L. J.; Gores, G. J. Hepatocyte apoptosis is a pathological feature of human alcoholic hepatitis. J. Hepatol. 2001, 34, 248-253.
121. Ziol, M.; Teppe, M.; Lohez, M.; Arcangeli, G.; Ganne, N.; Christidis, C.; Trichet, J. C.; Beaugrand, M.; Guillet, J. G.; Guettier, C. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J. Hepatol. 2001, 34, 254-260.
122. Bantel, H.; Lugerin, A.; Poremba, C.; Lugering, N.; Held, J.; Domschke, W.; Schulze-Osthoff, K. Caspase activation correlates with the degree of inflammatory injury in chronic hepatitis C infection. Hepatology 2001, 34, 758-767.
123. Pianko, S.; McCaughan, G.; Sievert, W.; McHutchinson, J. Apoptosis and viral hepatitis. Viral Hep. Rev. 2000, 6, 1-17.
124. Feldstein, A. E.; Canbay, A.; Angulo, P.; Taniai, M.; Burgart, L. J.; Lindor, K. D.; Gores, G. J. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125, 437-443.
125. Gao, W.; Bentley, R. C.; Madden, J. F.; Clavien, P. A. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology 1998, 27, 1652-1660.
126. Natori, S.; Selzner, M.; Valentino, K. L.; Fritz, L. C.; Srinivasan, A.; Clavien, P. A.; Gores, G. J. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 1999, 68, 89-96.
127. Hoglen, N. C.; Hirakawa, B. P.; Fisher, C. D.; Weeks, S.; Srinivasan, A.; Wong, A. M.; Valentino, K. L.; Tomaselli, K. J.; Bai, X.; Karanewsky, D. S.; Contreras, P. C. Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J. Pharm. Exp. Ther. 2001, 297, 811-818.
128. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364, 806-809.
129. Srinivasan, A.; Roth, K. A.; Sayers, R. O.; Shindler, K. S.; Wong, A. M.; Fritz, L. C.; Tomaselli, K. J. In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system. Cell Death Diff. 1998, 5, 1004-1016.
130. Hoglen, N. C.; Chen, L. S.; Fisher, C. D.; Hirakawa, B. P.; Gro T.; Contreras, P. C. Characterization of IDN-6556 (3-{2-[(2-tk-Butyl-phenylaminooxalyl) -amino]-propionylamino}-4-oxo-5-(2,3,4,5,6 -tetrafluoro-phenoxy)-pentanoic Acid): a liver-targeted caspase inhibitor. J. Pharm. Exp. Ther. 2003, 309, 634-640.
131. Linton, S. D.; Aja, T.; Armstrong, R. A.; Bai, X.; Chen, L. S.; Chen, N.; Ching, B.; Contreras, P.; Diaz, J. L.; Fisher, C. D.; Fritz, L. C.; Gladstone, P.; Groessl, T.; Gu, X.; Herrman, J.; Hirakawa, B. P.; Hoglen, N. C.; Jahangiri, K. G.; Kalish, V. J.; Karanewsky, D. S.; Kodandapani, L.; Krebs, J.; McQuiston, J.; Meduna, S. P.; Nalley, K.; Robinson, E. D.; Sayers, R. O.; Sebring, K.; Spada, A. P.; Ternansky, R. J.; Tomaselli, K. J.; Ullman, B. R.; Valentino, K. L.; Weeks, S.; Winn, D.; Wu, J. C.; Yeo, P.; Zhang, C. Z. First-in-class pan caspase inhibitor developed for liver disease. J. Med. Chem. 2005, 48, 6779-6782.
132. Mignon, A.; Rouquet, N.; Fabre, M.; Martin, S.; Pages, J. C.; Dhainaut, J. F.; Kahn, A.; Briand, P.; Joulin, V. LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am. J. Respir. Crit. Care Med. 1999, 159, 1308-1315.
133. Canbay, A.; Feldstein, A.; Baskin-Bey, E.; Bronk, S. F.; Gores, G. J. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharm. Exp. Ther. 2004, 308, 1191-1196,
134. Natori, S.; Selzner, M.; Valentino, K. L.; Fritz, L. C.; Srinivasan, A.; Clavien, P. A.; Gores, G. J. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 1999, 68, 89-96.
135. Natori, S.; Higuchi, H.; Contreras, P.; Gores, G. J. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury, Liver Transplantation 2003, 9, 278-284.
136. Valentino, K. L.; Gutierrez, M.; Sanchez, R.; Winship, M. J.; Shapiro, D. A. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharm. Thera. 2003, 41, 441-449.
137. Schiff, E. R.; Pockros, P.; Shiffman, M. L.; McHutchinson, J.; Gish, R.; Afdhal, N. H.; Makhviladze, M.; Huyghe, M.; Hecht, D.; Oltersdorf, T.; Shapiro, D. Oral IDN-6556, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients. Gastroenterology 2004, 126, Suppl. 2.